Medical Devices. These reports were restricted to drugs for which at least four cases were found. After case validation, 159 reports remained (validated dataset) and were compared with the basic dataset (n = 12.168 reports) using inferential statistics.
| INTRODUCTION
According to the allergy for global use nomenclature, anaphylaxis is defined as a severe, life-threatening generalized or systemic hypersensitivity reaction 1 resembling an immediate-type reaction. 2, 3 The distal pathophysiological pathway in immune-mediated and non-immune-mediated anaphylaxis involves the release of mediators such as histamine, tryptase, and other bioactive mediators from basophils and mast cells. 4 Drugs rank either second 5, 6 or third [7] [8] [9] behind food and insect venoms as elicitors of anaphylaxis in children. One study reported an incidence of 0.5/100 000 person-years based on the clinical evaluation of these cases. 10 Antibiotics, particularly beta-lactams, and nonsteroidal antiinflammatory drugs (NSAIDs) are reported as frequent elicitors of drug-induced anaphylaxis in children. [11] [12] [13] [14] [15] However, these observations are based on a limited number of anaphylaxis cases in children (less than 100).
Some publications have reported atopy and allergy as risk factors for severe courses of anaphylaxis 16, 17 whereas others have not. 12, 14, 15, 18 However, risk factors and cofactors may differ between age groups or according to the underlying pathophysiology and are not sufficiently studied in children. 19 This paucity of data prompted us to further investigate druginduced anaphylaxis in children on a larger scale and over a longer The main objective was to analyze validated cases with regard to incriminated drugs, clinical phenotype, and associated factors. One limitation of spontaneous ADR data is the lack of control groups. A further objective was thus to compare differences in incriminated drugs and characteristics between validated cases and a reference excluding anaphylactic reaction cases (basic dataset).
| MATERIAL AND METHODS

| BfArM's ADR database
As described earlier, 20, 21 physicians in Germany are obliged by their professional conduct code to report ADRs to their professional councils, which forward these reports to either BfArM (responsible for chemically defined drugs) 22 or Paul-Ehrlich-Institut (PEI) (responsible for monoclonal antibodies, vaccines, etc). 23, 24 These reports can also be reported directly to BfArM, PEI, or marketing authorization holders who then forward the reports to the authorities.
In BfArM's ADR database, drugs are coded according to the World Health Organization (WHO) Drug Dictionary and the Anatomical Therapeutic Chemical (ATC) classification system. 25 ADRs are coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology. 26 The data lock point of the present analysis was December 2016.
| Case identification
We identified all spontaneous ADR reports (no study reports) referring to children (0-17 years), registered between January 2000 and December 2016 and originating from Germany (n = 14 508). Subsequently, we selected all anaphylactic reaction cases (n = 505) by application of the Standardized MedDRA Query (SMQ) "anaphylactic reaction" (version 19.1 as of September 2016). 26 The 505 cases were restricted to reports where the "suspected/interacting" drug was reported more than three times in order to exclude influence by single reports. This resulted in 242 reports. All ADR reports coded as medication errors or with evidence of ADRs due to intentional suicide/self-injury were excluded by application of respective SMQs (pertains to each of the three datasets).
| Validation of cases with anaphylactic reactions
The 242 reports were assessed by one of two (either B.S. or W.F-B)
board-certified specialists in dermatology and allergology. Only cases in which (a) the correctness of the diagnosis "anaphylactic reaction"
according to a national guideline 3 and (b) the causal relationship with the incriminated drug according to WHO criteria 27 was at least possible were considered for further analysis. Reports with only few symptoms or reports where symptoms were already transformed into the diagnosis "anaphylaxis" were also considered if -respective treatment or treatment in an intensive/emergency care unit was reported,
-the patient had to be hospitalized,
-the event occurred under medical surveillance (eg, during anesthesia),
-the case was reported as life-threatening, or
KEY POINTS
• Only a few studies have investigated drug-induced anaphylactic reactions in children.
• The adverse drug reaction (ADR) database of the
German Federal Institute for Drugs and Medical
Devices provided the opportunity to examine this rare ADR on a larger scale.
• Intravenous administration was noted for 38% of incriminated drugs. In 13.8% of cases (11.3% if excluding repeated readministration in one person), previous hypersensitivity to the drug had been reported, and these cases appeared to be more severe than cases designated as "drug never used before."
• Antibiotics, analgesics, and MRI contrast media were most frequently suspected of having induced the anaphylactic reaction in validated cases.
• Cefaclor accounted for 27% and amoxicillin for 8.3% of cases induced by antibiotics, although exposure to amoxicillin seems to outweigh cefaclor exposure.
-the physician already had classified the anaphylactic reaction suggesting medical expertise concerning anaphylactic reactions.
For quality assurance, the final dataset was reviewed by a pharmacist.
Eventually, the validated dataset consisted of 159 cases including 164 incriminated drugs (equal causal probability for two drugs in five cases). The analysis of the incriminated drugs and routes of administration referred to the 164 drugs, whereas all other analyses referred to the 159 cases (see Figure 1 ).
| Quality of validated cases
The completeness of data in the validated cases was assessed according to a published score. 28 Calculation of the score was modified as it was not computed for every reported drug-ADR pair (in case more than one ADR had been reported) and then aggregated to an average, to yield an overall score for the corresponding report. Instead, since our analysis focused on anaphylactic reactions, the calculation of the score referred only to the diagnosis anaphylactic reaction. A complete- . Most data in the variable dose (30.8% of reports) was missing.
| Generation and comparison of additional datasets
In order to address the lack of a control group, we generated a reference group ("basic dataset") containing all other ADR reports on children 0 to 17 years excluding the 505 cases identified by the SMQ "anaphylactic reaction" (n = 12 168 reports). In addition, we created the "all-anaphylactic reactions" dataset in order to examine whether differences between the basic dataset and the validated dataset might have resulted from the validation process or from restriction to reports with drugs reported in more than three cases. This dataset was based on the 505 identified anaphylactic reaction cases and finally resulted in 472 reports. The same predefined inclusion and exclusion criteria of cases were applied for both datasets.
The three datasets were compared with regard to basic character- 3 | RESULTS The drug classes most frequently suspected in the validated cases were less often reported in the basic dataset (antibiotics 30.2% vs 11%, analgesics/antipyretics 22.0% vs 5.6%; P values less than 0.001).
| Comparison of datasets
Intravenous administration was clearly more often reported in the validated compared with the basic dataset (38.4% versus 6.7%; P value less than 0.001, based on the number of suspected drugs) and differed depending on drug class.
For most parameters, larger (but similar) differences were observed between the validated and the basic dataset than between the all-anaphylactic and the basic dataset. However, the number of cases that reported the seriousness criterion death was larger in the all-anaphylactic (6.1%) than in the validated dataset (0.6%).
| Analysis of validated cases
| Demographic parameters
The mean age of validated cases was 8.9 years (SD = 5.4) ( Table 2 ).
Slightly more reports were found for preschoolers (≥3 to ≤6 years;
28.9%) and adolescents (≥16 to ≤17 years; 17.6%). Drug-related age and gender differences were observed, eg, mean age: iron (14.7 years); gender: MRI contrast media (14 females vs five males).
These gender differences were also observed in the stratified age groups (female 0-5 years: 38.2%; female 13-17 years: 62.7%).
| Classification and description of anaphylactic reactions
A total of 10.1% of the validated cases were classified as grade I, 67.3% as grade II, 17.0% as grade III, and 0.6% as grade IV. Grade I/II (moderate; 77.4%) and grade III/IV (severe; 17.6%) cases were pooled for subanalysis. More severe than moderate reactions were only reported in atracurium cases ( Table 3 ).
The most frequently reported symptom was dyspnea (35.8%; 57/159 cases) followed by urticaria (33.3%; 53/159). Differences were noted for analgesics/antipyretics (urticaria: 40.0%) and for atracurium cases (anaphylactic shock: 60.0%) ( Table 4) . Urticaria (43.6%) was the leading symptom reported for the age class 0 to 5 years, whereas this was dyspnea for age classes 6 to 12 (32.7%) and 13-17 years (33.3%) (data not shown). The largest number of reports designated as atopic/allergic was observed in the analgesics/antipyretics drug class (42.9%; 15/35; P < 0.05), followed by MRI contrast media (31.6%; 6/19) ( Table 4) , whereas only 14.6% (7/48; P < 0.05) of the antibiotic cases were designated as atopic/allergic. Three of five atracurium cases (rank 5) were classified as anaphylactic reactions grade III (1 grade IV (fatal outcome), 1 NOS); four out of five of these cases were in males.
| Atopy/allergy
| Drug-related findings
Four of seven iron-related cases referred to ferric carboxymaltose (intravenous; rank 6) and one case each to ferric gluconate (intravenous), ferric dextran (intravenous), and ferric sulfate (oral). In all cases, the reaction occurred within 30 minutes.
Four cases of anaphylactic reaction after intravenous corticosteroid therapy with asthma as comorbidity (rank 6) were identified.
Another four cases reported anaphylactic reactions (3/4 grade II, 1/4 NOS) after topical application of an ointment with the ingredients methyl nicotinate and Symphytum officinale (rank 6).
In 15.1% (24/159) of the reports, the drug had never been taken previously ( 
| DISCUSSION
The present study analyzed 159 validated cases of drug-induced anaphylactic reactions in children and compared this dataset with a d In some cases, more than one drug is reported as suspected. Therefore, the number of reported drugs exceeds the number of reports.
e There are also other primary sources besides physicians or consumer/non-health care personnel (HCPs). Thus the percentages do not yield 100%.
f
The "seriousness" assessment may not reflect the clinical severity of the reaction since they refer to the legal definition of the Medicinal Products Act: An adverse drug reaction (ADR) is considered serious when the ADR results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect. One case may contain more than one of these criteria.
g Twenty-nine cases with the seriousness criterion "death" were determined; 14 of these cases were assessed within the validation process, leading to the exclusion of 13 cases. The remaining 15 cases were excluded because of the criterion "drug was not reported more than three times."
h Frequency distributions of administration routes refer to the total number of drugs per dataset.
i First, the reported suspected/interacting drug subgroups of the validated dataset were identified. Then, respective ATC codes were assigned to the identified drug subgroups. Subsequently, their ATC codes were applied for the stratification of drug subgroups in the other two datasets. Stratification with the suspected/interacting drugs by their active ingredient name only (without application of their ATC code) yielded similar results.
j Ibuprofen is assigned to more than one ATC class. Thus, not all cases could be retrieved by ATC code N02 (analgesics), and ibuprofen was identified by its active ingredient name.
*Chi-squared test/Fischer exact test; P < 0.001. Further information for calculation of P values is included in Section 2.7. This table shows the validated cases (n = 159; validated dataset) stratified by drug class and seriousness criteria, age and gender, proportion of intravenous administration, and drug-specific history. In 48 antibiotic cases, 49 antibiotics (one case with cefotaxime and cefixim) were reported. One case reporting cefaclor and ibuprofen as suspected drugs was also counted for the drugs class analgesics. In 35 analgesic cases, 36 analgesics (one case with ibuprofen and metamizole) were reported. One case reporting cefaclor and ibuprofen as suspected drugs was also counted for the drug class antibiotics. One report included metamizole and metoclopramide as suspected drugs and was therefore also counted in the group "all other cases." One of the 5 atracurium reports included atracurium and propofol as suspected drugs and, thus, was also counted in the group "all other cases." In 36 "all other cases," atracurium and propofol were reported as suspected drugs and, hence, were also counted for atracurium. One report included metamizole and metoclopramide as suspected drugs and was therefore also counted in the group analgesics.
b A total of 159 case reports contained 164 suspected drugs. Cases with more than one drug were counted in each drug class. However, they were not counted twice if they belonged to the same drug class. Therefore, the sum of cases of all drug subgroups exceeds 159 cases.
c Twelve case reports for alglucosidase. Among these 12 cases, there was one patient accounting for five cases (each at a different date). In these cases, there was no evidence that the reactions occurred in context with a desensitization procedure.
d
The "seriousness" assessment may not reflect the clinical severity of the reaction since they refer to the legal definition of the Medicinal Products Act: An adverse drug reaction (ADR) is considered serious when the ADR results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect. One case may contain more than one of these criteria. The relative distributions if a "drug was tolerated" or "not tolerated" or "tolerated is unknown after previous administration" refer to the number reporting "drug administered before." The 13.8% (22/159) cases, which reported previous hypersensitivity to the administered drug, included repeated readministration (four times) in one patient (assigned to the drug subgroup alglucosidase). A total of 11.3% (18/159) of cases remained if these four reports were excluded. *Chi-squared test/Fischer exact test; P < 0.05. Further information on calculation of P values is included in Section 2.7.
reference (basic dataset) containing all ADR reports excluding anaphylactic reactions.
| Comparison of datasets
The drugs most frequently suspected in the validated dataset compared with the basic dataset were antibiotics (30.2% vs 11.0%), analgesics/antipyretics (22.0% vs 5.6%), and MRI contrast media (11.9% vs 0.5%). Hence, these may play a prominent role in druginduced anaphylactic reactions in children as also reported in literature. 5, 13, 30, 31 Different drug exposure rates may also account for this finding. However, in Germany, analgesics and antiinfectives ranked only fourth and eighth in this respect. 32 Intravenous administration was reported more frequently in the validated compared with the basic dataset (38.4% versus 6.7%).
Hence, intravenous administration may entail a higher risk for anaphylactic reactions as also reported in other investigations 14 ; alternatively, drugs with a higher risk may be more likely to be given intravenously.
In contrast to the basic dataset, the average number of cases reporting anaphylactic reactions did not increase in the past 16 years (validated dataset). Although this finding is reassuring, it cannot be concluded whether it also applies in real life because of the limitations of the spontaneous reporting system.
The reports of anaphylactic reactions appeared to be more severe based on the legally defined criteria of seriousness life-threatening and hospitalization but were astonishingly less frequently reported as fatal
). This particular finding may however result from the validation since fatal outcome was even higher (6.1%)
in the all-anaphylactic-reaction dataset (not validated).
The differences between the validated and the basic dataset were mostly similar but larger than between the all-anaphylactic and the basic datasets. Therefore, the discussed differences between the basic and the validated dataset are unlikely to have resulted from the validation process. On the other hand, validation improves data quality, as could be seen with regard to the outcome fatal. 32 However, we did observe a gender predominance for certain drugs (eg, female gender: iron). Since literature only reports a significant gender difference in drug exposure for drugs related to the urogenital system/sexual hormones (contraceptives), 32 the observed differences could be due to chance or unknown factors.
| Analysis of the validated dataset
Largely in accordance with a recent study, 12 the majority of ana- A total of 159 case reports contained 164 suspected drugs. Cases with more than one drug were counted in each drug class. However, they were not counted twice if they belonged to the same drug class.
c Twelve case reports for alglucosidase. Among these 12 cases there was one patient accounting for five cases (each at a different date). In these cases there was no evidence that the reactions occurred in context with a desensitization procedure. *Chi-squared test/Fischer exact test; P < 0.05. Further information on the calculation of P values is included in Section 2.7. 40, 41 or by neuromuscular blocking agents like atracurium. 38, 43 In this table, the validated cases (n = 159; validated dataset) are stratified according to drug class, the reported underlying allergic/atopic conditions, the assumed underlying pathophysiological mechanisms, and the three most frequently reported symptoms.
b A total of 159 case reports contained 164 suspected drugs. Cases with more than one drug were counted in each drug class. However, they were not counted twice if they belonged to the same drug class.
This group also contained four fluoroquinolone cases. Both immune-mediated and non-immune-mediated reactions have been described for fluoroquinolones. The first is reported as being more common.
e
Five subtypes of NSAID-induced hypersensitivity reactions have been proposed, 35 including non-immune-mediated and immune-mediated reactions. In one publication, it is assumed that non-immune-mediated cases account for more than 75% of cases. Reported symptoms by analyzing the assigned preferred terms. The diagnosis "anaphylactic reaction" is based on specific symptoms reported. Some symptoms may be reported more often than others. In some cases only the diagnosis "anaphylactic reaction" is reported.
*Chi-squared test/Fischer exact test; P < 0.05. Further information on the calculation of P values is included in Section 2.7.
antipyretics-induced cases. Regarding the differentiation of NSAIDinduced hypersensitivity, 35 this finding could reflect a higher proportion of the "NSAID-induced urticaria/angioedema" type or the "NSAID-exacerbated cutaneous disease" type in our cases. Children aged 0 to 5 years more often reported urticaria and vomiting than older age classes. In contrast, decreased blood pressure was more frequent in adolescents (13-17; data not shown) as also reported by others.
11
About one quarter of the cases was designated as atopic/allergic; similar results were reported in other studies. 8, 36 Although preferential underreporting cannot be excluded, atopy was not confirmed as a risk factor for severe reactions in our study, which is also in accordance with literature. 12, 15, 18, 37 Atopic patients are IgE antibody high responders. 1 We found a lower percentage (14.6%) of patients reporting atopy/allergy in "antibiotics cases" with assumed preferential immune-mediated pathophysiology (according to literature 5 ). On the other hand, in the "analgesics/antipyretics cases" with assumed preferential nonimmune-mediated pathophysiology (according to literature 5, 35, [38] [39] [40] [41] [42] [43] ), a higher percentage (42.9%) was observed. No significant association with atopy for beta-lactam allergy in children 44, 45 was found in other studies either. Instead, varying associations of atopy with different phenotypes of NSAID-induced hypersensitivity have been described, suggesting that atopy may predispose to selected forms of NSAID hypersensitivity. 46 However, in one study in patients of all ages, no differences were found. 14 Therefore, our findings could also be due to chance or varying documentation. 47 However, because of the limitations of the spontaneous reporting system, we cannot determine whether this finding reflects drug-preferential reporting, different potentials of these drugs to induce anaphylactic reactions, or other reasons.
All five atracurium cases were designated as serious (one fatal). It remains unclear whether atracurium is associated with more severe anaphylactic reactions or whether severe anaphylactic reactions occurring under anesthesia are more likely to be noticed/reported. The latter would also apply to other drugs used in anesthesia, which were not seen in our analysis. Nevertheless, our finding could also reflect different exposure
rates. An analysis in France 48 also reported a higher ratio of grade III/IV hypersensitivity reactions for neuromuscular blocking agents.
In 13.8% of the cases (11.3% if excluding reported readministration in one person), previous hypersensitivity to the drug had been reported, and these reactions appeared to be more severe than cases designated as "drug never used before." Hence, serious anaphylactic reactions Finally, we cannot rule out that there may have been cases for which no alternative medication was available.
The strengths of the spontaneous reporting system encompass the large number of potential cases, the inclusion of vulnerable patient populations (eg, children), and the possibility to detect very rare/long latency ADRs. Its limitations include underreporting, preferential and stimulated reporting, a varying degree of documentation in the reports, and the impossibility to calculate ADR frequencies due to lack of exposure data. 49 Hence, epidemiological studies not based on spontaneous data are usually required to further investigate the signals observed.
In conclusion, a heterogeneous clinical phenotype with differences in associated factors was observed, suggesting different underlying mechanisms triggered by the different drug groups. Future studies may thus focus on defined drug groups. Exploration of larger databases like EudraVigilance could be helpful in order to gain access to further of such cases.
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